A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects
Status:
Completed
Trial end date:
2019-06-27
Target enrollment:
Participant gender:
Summary
The Study Drug is an investigational drug which is being developed by OliX Pharmaceuticals
Inc., with an aim to help people who develop hypertrophic scars (a type of permanent scar) in
the future. Hypertrophic scars are formed when a wound becomes red, raised, and itchy before
it eventually heals. These scars tend to develop due to disease, surgical operations, or
burns. Available physical treatment methods to remove scars include surgery or laser therapy;
however these are often accompanied by further complications including pain and recurrence of
the scar and can be costly. Similarly, therapeutic agents such as ointments or oral drugs
have little to no effect in preventing or treating hypertrophic scars. The aims of this Study
are to determine the safety of the Study Drug and any side effects that might be associated
with it, and how much of the Study Drug gets into the bloodstream and how long it takes the
body to remove it.
The healthy adult subjects can participate in this study in the age between 18 and 60 years
old in the UK.
This study will be conducted in 2 parts, Part A and B. Part A will be a single subcutaneous
or intradermal dose, dummy controlled study. Part B will be a multiple intradermal dose,
dummy controlled study.